Effects of lactic acid bacteria intake on bone metabolism markers in postmenopausal women: an exploratory study

Not Applicable

• Conditions: /A

• Registration Number: JPRN-UMIN000048433
• Lead Sponsor: Meiji Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-08-09
• Study Completion: 2022-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

1.Subjects with food allergies 2.Subjects with lactose intolerance 3.Subjects who have menopause before 43 years old 4.Subjects who have been diagnosed with osteoporosis 5.Subjects who have undergone bilateral oophorectomy 6.Subjects who suffer from serious disorders of liver, kidney, heart, lung, or digestive organs (including gastric resection), diabetes, rheumatoid arthritis, neurological/mental diseases, endocrine diseases, or other serious and/or progressive diseases. 7.Subjects who have been diagnosed with congenital bone metabolism diseases (osteogenesis imperfecta, Marfan syndrome, etc.) 8.Subjects who have a history of bone fracture within the past year 9.Subjects who have been receiving long-term medical treatment (hospitalization, etc.) within the past year. 10.Subjects currently receiving medicine treatment known to affect bone metabolism (hormone therapy, steroids (last 6 months), warfarin, SSRI, anticonvulsants, methotrexate, heparin, beta-blockers, alpha-blockers, alpha, beta-blockers, etc.) 11.Heavy drinkers (weekly average of 30 g/day or more of pure alcohol) 12.Smoker 13.Subjects who regularly use medicines, health foods or supplements that may affect this study (e.g. intestinal regulators, calcium, magnesium, vitamin D, vitamin K, soy isoflavone, foods/beverages/supplements containing lactic acid bacteria (e.g. yogurt), foods/beverages/supplements containing prebiotics such as oligosaccharides , etc.) 14.Subjects with severe vitamin D deficiency (serum 25-OH-vitamin D less than 10 ng/ml) 15.Subjects who participate in other clinical trials within the past 3 months or have plans to participate in other clinical trials during this study period 16.Subjects who determine ineligible by the principal investigator or the co-investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified